{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:34:29Z","timestamp":1740173669551,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/omcr\/omz016","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T08:20:39Z","timestamp":1553847639000},"source":"Crossref","is-referenced-by-count":6,"title":["Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer"],"prefix":"10.1093","volume":"2019","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-8468","authenticated-orcid":false,"given":"Ajaz","family":"Bulbul","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Hematology\/Oncology, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, USA"},{"name":"Department of Internal Medicine, Department of Hematology\/Oncology, University of New Mexico, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"key\n\t\t\t\t2019032908194499800_omz016C1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","article-title":"Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy","volume":"1","author":"Lo","year":"2015","journal-title":"JAMA Oncol"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C4","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2217\/fon.15.118","article-title":"Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2015","journal-title":"Future Oncol"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"key\n\t\t\t\t2019032908194499800_omz016C10","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.156.6.1755","article-title":"Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets","volume":"156","author":"Houghton","year":"1982","journal-title":"J Exp Med"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2019\/3\/omz016\/28244607\/omz016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T08:20:41Z","timestamp":1553847641000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omz016\/5423012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,29]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omz016","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3,1]]}}}